Selected research
Industry Research
Anti-Smoking Products Industry Research Report 2026
Market perspective
The global Anti-Smoking Products market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Anti-Smoking Products market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Anti-Smoking Products market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Anti-Smoking Products market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Anti-Smoking Products include Takeda pharmaceutical, Novartis International, Pfizer, GSK, VMR products, VaporCorp, Revolymer plc, NJOY and McNeil AB, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Anti-Smoking Products market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Anti-Smoking Products.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-Smoking Products Market by Company
Takeda pharmaceutical
Novartis International
Pfizer
GSK
VMR products
VaporCorp
Revolymer plc
NJOY
McNeil AB
Lorillard
Imperial Tobacco
Elder Pharma
Cipla
Anti-Smoking Products Segment by Type
Drug therapy
Nicotine Replacement Therapy
E-cigarettes
Anti-Smoking Products Segment by Application
Smokers aged 65 years or older
Smokers aged 45–64
Smokers aged 25–44
Smokers aged 18–24
Anti-Smoking Products Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Smoking Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Smoking Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Smoking Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Anti-Smoking Products companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drug therapy
- Nicotine Replacement Therapy
- E-cigarettes
Applications
- Smokers aged 65 years or older
- Smokers aged 45–64
- Smokers aged 25–44
- Smokers aged 18–24
Companies covered
- Takeda pharmaceutical
- Novartis International
- Pfizer
- GSK
- VMR products
- VaporCorp
- Revolymer plc
- NJOY
- McNeil AB
- Lorillard
- Imperial Tobacco
- Elder Pharma
- Cipla
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Anti-Smoking Products by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Drug therapy
- 2.2.3 Nicotine Replacement Therapy
- 2.2.4 E-cigarettes
- 2.3 Anti-Smoking Products by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Smokers aged 65 years or older
- 2.3.3 Smokers aged 45–64
- 2.3.4 Smokers aged 25–44
- 2.3.5 Smokers aged 18–24
- 2.4 Assumptions and Limitations
3 Anti-Smoking Products Breakdown Data by Type
- 3.1 Global Anti-Smoking Products Historic Market Size by Type (2021-2026)
- 3.2 Global Anti-Smoking Products Forecasted Market Size by Type (2027-2032)
4 Anti-Smoking Products Breakdown Data by Application
- 4.1 Global Anti-Smoking Products Historic Market Size by Application (2021-2026)
- 4.2 Global Anti-Smoking Products Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Anti-Smoking Products Market Perspective (2021-2032)
- 5.2 Global Anti-Smoking Products Growth Trends by Region
- 5.2.1 Global Anti-Smoking Products Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Anti-Smoking Products Historic Market Size by Region (2021-2026)
- 5.2.3 Anti-Smoking Products Forecasted Market Size by Region (2027-2032)
- 5.3 Anti-Smoking Products Market Dynamics
- 5.3.1 Anti-Smoking Products Industry Trends
- 5.3.2 Anti-Smoking Products Market Drivers
- 5.3.3 Anti-Smoking Products Market Challenges
- 5.3.4 Anti-Smoking Products Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Anti-Smoking Products Players by Revenue
- 6.1.1 Global Top Anti-Smoking Products Players by Revenue (2021-2026)
- 6.1.2 Global Anti-Smoking Products Revenue Market Share by Players (2021-2026)
- 6.2 Global Anti-Smoking Products Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Anti-Smoking Products Head Office and Area Served
- 6.4 Global Anti-Smoking Products Players, Product Type & Application
- 6.5 Global Anti-Smoking Products Manufacturers Established Date
- 6.6 Global Anti-Smoking Products Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Anti-Smoking Products Market Size (2021-2032)
- 7.2 North America Anti-Smoking Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Anti-Smoking Products Market Size by Country (2021-2026)
- 7.4 North America Anti-Smoking Products Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Anti-Smoking Products Market Size (2021-2032)
- 8.2 Europe Anti-Smoking Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Anti-Smoking Products Market Size by Country (2021-2026)
- 8.4 Europe Anti-Smoking Products Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-Smoking Products Market Size (2021-2032)
- 9.2 Asia-Pacific Anti-Smoking Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Anti-Smoking Products Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Anti-Smoking Products Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Anti-Smoking Products Market Size (2021-2032)
- 10.2 South America Anti-Smoking Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Anti-Smoking Products Market Size by Country (2021-2026)
- 10.4 South America Anti-Smoking Products Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-Smoking Products Market Size (2021-2032)
- 11.2 Middle East & Africa Anti-Smoking Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Anti-Smoking Products Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Anti-Smoking Products Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda pharmaceutical
- 12.1.1 Takeda pharmaceutical Company Information
- 12.1.2 Takeda pharmaceutical Business Overview
- 12.1.3 Takeda pharmaceutical Revenue in Anti-Smoking Products Business (2021-2026)
- 12.1.4 Takeda pharmaceutical Anti-Smoking Products Product Portfolio
- 12.1.5 Takeda pharmaceutical Recent Developments
- 12.2 Novartis International
- 12.2.1 Novartis International Company Information
- 12.2.2 Novartis International Business Overview
- 12.2.3 Novartis International Revenue in Anti-Smoking Products Business (2021-2026)
- 12.2.4 Novartis International Anti-Smoking Products Product Portfolio
- 12.2.5 Novartis International Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Anti-Smoking Products Business (2021-2026)
- 12.3.4 Pfizer Anti-Smoking Products Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 GSK
- 12.4.1 GSK Company Information
- 12.4.2 GSK Business Overview
- 12.4.3 GSK Revenue in Anti-Smoking Products Business (2021-2026)
- 12.4.4 GSK Anti-Smoking Products Product Portfolio
- 12.4.5 GSK Recent Developments
- 12.5 VMR products
- 12.5.1 VMR products Company Information
- 12.5.2 VMR products Business Overview
- 12.5.3 VMR products Revenue in Anti-Smoking Products Business (2021-2026)
- 12.5.4 VMR products Anti-Smoking Products Product Portfolio
- 12.5.5 VMR products Recent Developments
- 12.6 VaporCorp
- 12.6.1 VaporCorp Company Information
- 12.6.2 VaporCorp Business Overview
- 12.6.3 VaporCorp Revenue in Anti-Smoking Products Business (2021-2026)
- 12.6.4 VaporCorp Anti-Smoking Products Product Portfolio
- 12.6.5 VaporCorp Recent Developments
- 12.7 Revolymer plc
- 12.7.1 Revolymer plc Company Information
- 12.7.2 Revolymer plc Business Overview
- 12.7.3 Revolymer plc Revenue in Anti-Smoking Products Business (2021-2026)
- 12.7.4 Revolymer plc Anti-Smoking Products Product Portfolio
- 12.7.5 Revolymer plc Recent Developments
- 12.8 NJOY
- 12.8.1 NJOY Company Information
- 12.8.2 NJOY Business Overview
- 12.8.3 NJOY Revenue in Anti-Smoking Products Business (2021-2026)
- 12.8.4 NJOY Anti-Smoking Products Product Portfolio
- 12.8.5 NJOY Recent Developments
- 12.9 McNeil AB
- 12.9.1 McNeil AB Company Information
- 12.9.2 McNeil AB Business Overview
- 12.9.3 McNeil AB Revenue in Anti-Smoking Products Business (2021-2026)
- 12.9.4 McNeil AB Anti-Smoking Products Product Portfolio
- 12.9.5 McNeil AB Recent Developments
- 12.10 Lorillard
- 12.10.1 Lorillard Company Information
- 12.10.2 Lorillard Business Overview
- 12.10.3 Lorillard Revenue in Anti-Smoking Products Business (2021-2026)
- 12.10.4 Lorillard Anti-Smoking Products Product Portfolio
- 12.10.5 Lorillard Recent Developments
- 12.11 Imperial Tobacco
- 12.11.1 Imperial Tobacco Company Information
- 12.11.2 Imperial Tobacco Business Overview
- 12.11.3 Imperial Tobacco Revenue in Anti-Smoking Products Business (2021-2026)
- 12.11.4 Imperial Tobacco Anti-Smoking Products Product Portfolio
- 12.11.5 Imperial Tobacco Recent Developments
- 12.12 Elder Pharma
- 12.12.1 Elder Pharma Company Information
- 12.12.2 Elder Pharma Business Overview
- 12.12.3 Elder Pharma Revenue in Anti-Smoking Products Business (2021-2026)
- 12.12.4 Elder Pharma Anti-Smoking Products Product Portfolio
- 12.12.5 Elder Pharma Recent Developments
- 12.13 Cipla
- 12.13.1 Cipla Company Information
- 12.13.2 Cipla Business Overview
- 12.13.3 Cipla Revenue in Anti-Smoking Products Business (2021-2026)
- 12.13.4 Cipla Anti-Smoking Products Product Portfolio
- 12.13.5 Cipla Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst